Skin & cosmetic
Palmitoyl Tripeptide-1
Pal-GHK, Matrixyl component
Palmitoyl Tripeptide-1 is a lipidated form of the GHK tripeptide, used in anti-ageing skincare and usually paired with Palmitoyl Tetrapeptide-7 in the formulation sold as Matrixyl 3000.
Also known as: Pal-GHK, palmitoyl oligopeptide, Matrixyl
- Status
- Palmitoyl Tripeptide-1 is used as a cosmetic or over-the-counter ingredient, not as an approved drug.
- Evidence
- Early human data. Only small or early-phase studies in people so far.
- Half-life
- Not applicable — acts locally in skin.
- How it's taken
- Topical, in a leave-on serum or cream
- Mechanism
- Cosmetic / topical
- Pathways
- Collagen Synthesis
How Palmitoyl Tripeptide-1 works
The GHK sequence is a fragment of type I collagen released during tissue damage, where it acts as a signal that collagen has been degraded and should be replaced. Attaching a palmitic acid chain increases lipophilicity to aid passage through the stratum corneum. In cell culture it upregulates collagen I, collagen IV and fibronectin production by dermal fibroblasts.
What research has looked at
- The signalling rationale is coherent: the peptide is a natural collagen breakdown fragment, so the skin already interprets it as a repair signal.
- Fibroblast studies consistently show increased extracellular matrix protein synthesis.
- Lipidation measurably improves penetration relative to the unmodified tripeptide.
- It has an excellent tolerability record in cosmetic use and does not cause the irritation associated with retinoids.
Evidence level: Early human data. Only small or early-phase studies in people so far. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Cosmetic peptide claims are supported largely by manufacturer-funded studies with small numbers and short duration; independent replication is uncommon.
- Skin penetration is the central unresolved question for topical peptides — most are too large and too hydrophilic to cross the stratum corneum efficiently, and formulation determines far more than the peptide itself.
- Effects on visible wrinkles are modest and develop over months of consistent use; it is not comparable to a retinoid or to a procedural intervention.
- Concentration in finished products is rarely disclosed, and many products contain amounts far below those used in the supporting studies.
- It is a cosmetic ingredient, not a drug, and is not evaluated by the FDA for efficacy.
Sources
- PubMed research on palmitoyl tripeptide-1 Matrixyl collagen fibroblast · NIH · National Library of Medicine
- DrugBank record for palmitoyl tripeptide-1 · DrugBank
- Active clinical trials for palmitoyl tripeptide-1 · U.S. National Library of Medicine
Track Palmitoyl Tripeptide-1 in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Palmitoyl Tripeptide-1 FAQ
What is Palmitoyl Tripeptide-1?
Palmitoyl Tripeptide-1 is a lipidated form of the GHK tripeptide, used in anti-ageing skincare and usually paired with Palmitoyl Tetrapeptide-7 in the formulation sold as Matrixyl 3000.
How does Palmitoyl Tripeptide-1 work?
The GHK sequence is a fragment of type I collagen released during tissue damage, where it acts as a signal that collagen has been degraded and should be replaced. Attaching a palmitic acid chain increases lipophilicity to aid passage through the stratum corneum. In cell culture it upregulates collagen I, collagen IV and fibronectin production by dermal fibroblasts.
Is Palmitoyl Tripeptide-1 FDA approved?
No. Palmitoyl Tripeptide-1 is used as a cosmetic or over-the-counter ingredient, not as an approved drug. Evidence level: early human data. Only small or early-phase studies in people so far.
What is the half-life of Palmitoyl Tripeptide-1?
Reported half-life: Not applicable — acts locally in skin.
How is Palmitoyl Tripeptide-1 taken?
Topical, in a leave-on serum or cream.
What side effects have been reported with Palmitoyl Tripeptide-1?
Reported in the sources: Cosmetic peptide claims are supported largely by manufacturer-funded studies with small numbers and short duration; independent replication is uncommon; Skin penetration is the central unresolved question for topical peptides — most are too large and too hydrophilic to cross the stratum corneum efficiently, and formulation determines far more than the peptide itself; Effects on visible wrinkles are modest and develop over months of consistent use; it is not comparable to a retinoid or to a procedural intervention; Concentration in finished products is rarely disclosed, and many products contain amounts far below those used in the supporting studies; It is a cosmetic ingredient, not a drug, and is not evaluated by the FDA for efficacy.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.